Ind-Swift Ltd
Incorporated in 1986, Ind-Swift Ltd deals in manufacturing and exporting of pharmaceutical products
- Market Cap ₹ 134 Cr.
- Current Price ₹ 24.8
- High / Low ₹ 31.2 / 7.65
- Stock P/E
- Book Value ₹ -132
- Dividend Yield 0.00 %
- ROCE 8.28 %
- ROE %
- Face Value ₹ 2.00
Pros
Cons
- Company has low interest coverage ratio.
- Promoters have pledged 42.8% of their holding.
- Earnings include an other income of Rs.78.3 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|
308 | 263 | 270 | 398 | 411 | 473 | |
465 | 328 | 262 | 352 | 369 | 431 | |
Operating Profit | -157 | -65 | 8 | 45 | 42 | 42 |
OPM % | -51% | -25% | 3% | 11% | 10% | 9% |
13 | -246 | -20 | 24 | 72 | 78 | |
Interest | 19 | 16 | 7 | 57 | 60 | 63 |
Depreciation | 36 | 36 | 35 | 32 | 29 | 27 |
Profit before tax | -200 | -363 | -53 | -20 | 26 | 30 |
Tax % | -0% | -0% | -1% | -2% | 0% | |
-214 | -373 | -50 | -20 | 26 | 30 | |
EPS in Rs | -42.42 | -68.81 | -9.31 | -3.70 | 4.81 | 5.50 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | % |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -18% |
3 Years: | % |
TTM: | 5% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | 38% |
3 Years: | 81% |
1 Year: | 194% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|
Equity Capital | 10 | 11 | 11 | 11 | 11 | 11 |
Reserves | -270 | -641 | -688 | -731 | -716 | -724 |
Preference Capital | 14 | 14 | 14 | 14 | 14 | |
1,047 | 1,048 | 1,041 | 1,021 | 978 | 976 | |
268 | 246 | 251 | 331 | 376 | 376 | |
Total Liabilities | 1,055 | 665 | 615 | 632 | 649 | 639 |
374 | 342 | 311 | 236 | 216 | 205 | |
CWIP | 4 | 2 | 0 | 9 | 30 | 35 |
Investments | 39 | 39 | 46 | 64 | 54 | 54 |
638 | 281 | 258 | 323 | 349 | 346 | |
Total Assets | 1,055 | 665 | 615 | 632 | 649 | 639 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
-119 | -2 | 7 | 50 | 73 | |
10 | 4 | -6 | -18 | -29 | |
110 | -11 | -6 | -45 | -47 | |
Net Cash Flow | 0 | -8 | -5 | -13 | -3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Debtor Days | 451 | 151 | 113 | 83 | 93 |
Inventory Days | 151 | 86 | 108 | 120 | 150 |
Days Payable | 290 | 356 | 394 | 353 | 393 |
Cash Conversion Cycle | 311 | -119 | -173 | -149 | -150 |
Working Capital Days | 409 | -37 | -57 | -69 | -77 |
ROCE % | -14% | -4% | 8% |
Documents
Announcements
- Board Meeting Intimation for Notice Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations, 2015 9h
- Compliance Certificate As per Regulation 40 (9) & (10) Of SEBI (LODR) Regulations, 2015. 2d
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
10 Apr - Update on merger of the company with Ind Swift Laboratories Limited (Group Company)
- Clarification On Price Movement 10 Apr
-
Clarification sought from Ind-Swift Ltd
10 Apr - Exchange has sought clarification from Ind-Swift Ltd on April 10, 2024, with reference to Movement in Price.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
-
Financial Year 2008
from bse
Business Overview:[1]
Company has expertise in finished goods dosage, Active Pharmaceutical Ingredients (API’s) and herbal products. Company also diversified into multiple fields viz., Infrastructure, Printing, Packaging & Stationary, Education, and Media Publication with its every unit as an independent profit earning center